ArticleAnesthesiology2026
Trends in Use of Medications for Opioid Use Disorder among Commercially Insured U.S. Surgical Patients, 2016 to 2022.
Article in Anesthesiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThe optimal management of perioperative pain in patients using medications for opioid use disorder (MOUD) is unclear. To motivate and inform efforts to develop evidence-based guidelines for perioperative pain management in these patients, it is important to evaluate whether the prevalence of MOUD use in surgical patients is increasing and to identify which procedures have the highest rate of MOUD use.
methodsThis cohort study analyzed adults 18 to 64 yr undergoing 1 of 1,083 major surgical procedures from 2016 to 2022 from the Merative MarketScan Commercial Database, which includes commercial claims from 22 to 28 million privately insured patients annually. Annual changes in MOUD use from 1 to 180 days before surgery were evaluated using logistic regression models adjusting for patient demographics and comorbidities. For each procedure category, the prevalence of MOUD use among all instances of the procedure during 2016 to 2022 was calculated.
resultsAnalyses included 8,137,973 surgical admissions for 5,013,213 adults (59.9% female). The adjusted prevalence of MOUD use increased from 55.2 per 100,000 in 2016 to 99.8 per 100,000 in 2022 (adjusted annual change, 16.9 per 100,000 procedures; 95% CI, 14.0 to 19.8). Among 15,701 surgical admissions for patients using MOUD during 2016 to 2022, the most common type of MOUD was buprenorphine (13,193; 84.0%). Procedures with the highest rate of MOUD use were debridement (719.0 per 100,000 procedures), shoulder arthroplasty (579.4 per 100,000 procedures), lower extremity amputation (529.6 per 100,000 procedures), and hip or pelvis open fracture repair (497.6 per 100,000 procedures).
conclusionsIn this cohort study of surgical procedures among privately insured U.S. adults, the prevalence of MOUD use increased between 2016 and 2022, highlighting the importance of developing evidence-based guidelines for perioperative management of these patients. The high rates of MOUD use in common orthopedic procedures suggest that these guidelines may be particularly relevant to the practice of orthopedic surgeons.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.